As international research continues to unravel the complexity of breast cancer and its many sub-types, a steady stream of exciting new medicines targeting each type comes to market. Some countries adopt and publicly fund these quickly, but New Zealand does not. Government spending on medicines per capita is lower in New Zealand than in most OECD countries and access to new medicines has been low and slow.
Although campaigns by BCAC and other New Zealand breast cancer patient groups have resulted in funding for a few new breast cancer medicines, such as trastuzumab emtansine (Kadcyla®), palbociclib (Ibrance®) and fulvestrant (Faslodex®), there are still many that are not funded here. Some are available privately if a patient is able to pay for them.
Here we describe some medicines currently funded in Australia, but not in New Zealand. We also list breast cancer medicines that are recommended in European guidelines, but not funded in Australia or New Zealand. All these drugs offer potential advantages in quality and length of life for New Zealanders with breast cancer and would give oncologists additional options for optimising treatment of the different sub-types of breast cancer. Additionally, individual patients can vary widely in their responses to a medicine and their responses may also change over time. This is why it is vitally important for doctors to have a range of medicines in their toolkits, particularly for treating advanced breast cancer.
Breast cancer medicines funded in Australia and not New Zealand (September 2023)
CDK 4/6 inhibitors - ribociclib (Kisqali®), abemaciclib (Verzenio®) – CDK 4/6 inhibitors are a group of medicines that prevent over-proliferation of cancer cells by inhibiting enzymes that the cells need in order to divide. These drugs improve survival of those with advanced oestrogen receptor positive breast cancer. There are several on the market now, and each offers slightly different benefits.
After a petition to Parliament led by BCAC Committee Member Terre Nicholson and submissions to the Health Select Committee by Terre and other Metavivors during 2018/19, Pharmac finally called for tenders to supply one of the CDK 4/6 inhibitors to the New Zealand public health system. Ibrance® (palbociclib), supplied by Pfizer, won the tender and is the only CDK 4/6 inhibitor that is funded in New Zealand at present.
The other contender was Kisqali® (ribociclib), supplied by Novartis. It has been approved by Medsafe and is available in New Zealand but not publicly funded. The application to Pharmac for Kisqali funding has been assessed and placed on the ‘Only if cost neutral or cost saving’ list. There is no indication of when or if it might be funded (May 2023).
A third CDK 4/6 inhibitor, Verzenio® (abemaciclib, supplied by Lilly), has been classified by Medsafe but has not yet been approved for use in New Zealand. There is no current application with Pharmac to seek public funding for this medicine (May 2023).
As of July 2022, Australia had approved funding for all three CDK 4/6 inhibitors – Ibrance, Kisqali and Verzenio - for first- and second-line use with either an aromatase inhibitor or fulvestrant in patients with metastatic hormone receptor positive, HER2-negative breast cancer. In April 2023, Australia's Pharmaceutical Benefits Advisory Committee also recommended abemaciclib for treating hormone receptor positive, HER2-negative early breast cancer. All three CDK 4/6 inhibitors are also available via the National Health Service throughout the United Kingdom, but with some restrictions depending on which country the patient lives in.
In New Zealand Pharmac funds Ibrance with an endocrine partner (fulvestrant or an aromatase inhibitor) for advanced breast cancer, either first-line (as the first endocrine treatment for advanced breast cancer) or second-line (after the advanced breast cancer has relapsed or progressed on prior endocrine therapy).
Bevacizumab (Avastin®) inhibits the growth of blood vessels around tumours. It is used in the treatment of advanced triple negative breast cancer. It has Medsafe approval in New Zealand but is not funded by Pharmac.
Denosumab (Xgeva® or Prolia®) is a monoclonal antibody that reduces tumour formation and growth in people whose cancer has spread to the bones. Recent Australian research has shown this drug also has the potential to prevent breast cancer in people with a BRCA gene mutation who are at high risk of getting breast cancer.
This medicine is Medsafe approved but not funded in New Zealand for treatment of bone metastases. An application to Pharmac for its use in this way was lodged in 2018, but has been given a low priority by its clinical advisory team. It was approved by the United States Food and Drug Administration (FDA) in 2010 for prevention of skeletal events (fractures) in patients with bone metastases from solid tumours. It is funded in Australia for elderly patients with low bone density and people with osteoporosis who have had a fracture after minimal trauma.
Eribulin (Halaven®) is used to treat late-stage metastatic breast cancer that is hormone receptor-positive and HER2-negative that has previously been treated with anthracycline and taxane chemotherapies. It is a “non-taxane microtubule inhibitor” that kills cancer cells by inhibiting cell division. Eribulin has been registered and publicly funded in Australia since 2013 and was recommended for inclusion on the New Zealand Pharmaceutical Schedule in 2012 but is not funded in New Zealand. After discussions with BCAC, pharmaceutical company Eisai agreed to import eribulin under section 29 of the Medicines Act, has applied for Medsafe registration, and furthermore set up a cost share programme, which has significantly reduced the cost for patients. BCAC applied to Pharmac to have eribulin funded; but in November 2022 Pharmac declined this application. All is not lost, however, as BCAC has disputed Pharmac’s findings and Pharmac has agreed to refer the matter to their specialist Cancer Treatments Advisory Committee (CTAC). BCAC and Eisai will continue to follow up with Pharmac to try and get this medication funded for New Zealanders.
Everolimus (Afinitor®) is used in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in post-menopausal women, in conjunction with the aromatase inhibitor exemestane after failure of letrozole or anastrozole. It is only used in patients whose tumour has tested negative for HER2. Everolimus stops a particular protein called mTOR from working properly. mTOR controls other proteins that trigger cancer cells to grow.
Everolimus is not Medsafe approved or publicly funded for breast cancer in New Zealand. It has been funded in Australia since 2014. In July 2018 BCAC applied to Pharmac to have this medicine publicly funded. In July 2019, BCAC was informed that this application had been declined by Pharmac.
Ibandronate (Bondronat®) is a bisphosphonate used to reduce bone loss in those whose metastatic cancer has moved to their bones. It is funded specifically for breast cancer in Australia but not in New Zealand. Its approval by Medsafe NZ has lapsed.
Nab-paclitaxel (Abraxane®) is used to treat advanced breast cancer in people who have already received other medicines. It can also be used in those with early breast cancer. It is a taxane that fights cancer by interfering with cell division. Abraxane is a less toxic formulation of the taxane, paclitaxel (brand name Taxol®), with the advantage of causing reduced side effects as it is delivered in protein nanoparticles rather than the toxic solvent that paclitaxel and another taxane docetaxel (Taxotere®) are dissolved in. Abraxane is particularly helpful for patients who have an allergic reaction to paclitaxel or docetaxel.
Abraxane has been publicly funded in Australia since 2009. This medicine is available and Medsafe approved in New Zealand, but not publicly funded. In February 2018 BCAC applied to Pharmac to have Abraxane funded. In May 2019 Pharmac's Pharmacology and Therapeutics Advisory Committee (PTAC) recommended it be funded only if "cost-neutral" to weekly paclitaxel (the currently funded option). Meeting this price requirement would be extremely difficult because of the higher cost of creating a humanised nanoparticle albumin bound (nab) paclitaxel compared with the other taxanes which are simply dissolved in solvent. In July 2021 Pharmac's Cancer Treatments Advisory Committee (CTAC) re-examined the evidence for Abraxane and recommended it with high priority for those allergic to other taxanes and with medium priority for others with advanced breast cancer. The committee noted its faster infusion time reducing the burden on clinical resources, the clinical benefits, reduced toxicity and greater suitability of Abraxane over other taxanes. Abraxane is now the only breast cancer medicine that sits on Pharmac’s ‘Options for Investment’ list.
The company that owns Abraxane, Specialised Therapeutics, first applied for Pharmac funding in 2010. Over recent years they set up a cost share programme to make Abraxane more accessible to patients. However, they were unable to secure a meeting with Pharmac and after 13 years have given up on ever achieving funding in New Zealand, so have withdrawn the cost-share.
While it may seem there is now little hope for funding of Abraxane, BCAC has not yet given up. We believe it was discussed again at the April 2023 CTAC meeting so the possibility of funding for this medicine remains on the table.
Pegylated doxorubicin (Caelyx®) is a cytotoxic chemotherapy agent that has been formulated in liposomes so that it is less likely to cause side effects. In New Zealand, doxorubicin is funded but this pegylated version is not. Although applications to Pharmac for funding this medicine were made in 2006 and 2011, there has been no approval. BCAC understands that the sponsor of this product has given up on getting this treatment funded in New Zealand. It has been funded in Australia since 2003.
Pembrolizumab (Keytruda®) is an antibody used in cancer immunotherapy. It is one of a number of new medicines called checkpoint inhibitors that support the body’s immune system to recognise and destroy cancer cells. Some types of cancers have a protein on the cell surface that masks the cancer from the body’s immune system. Keytruda and other similar new drugs are designed to lock onto and deactivate this protein, exposing the cancer cells to the body’s immune system, allowing the body’s T-cells to destroy the cancer. Breast cancer clinical trials currently under way with Keytruda (KEYNOTE trials) and other similar drugs are producing very promising results, particularly in triple negative breast cancer that test positive for the tumour masking protein, PD-L1.
The FDA has approved Keytruda for use in both early and advanced triple negative breast cancer. In New Zealand, in August 2022 Medsafe approved Keytruda for high-risk early-stage triple negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment (before surgery) then continued on its own after surgery. Medsafe also approved Keytruda in combination with chemotherapy for treatment of advanced (metastatic) TNBC when tumours express PD-L1 (CPS ≥10). Keytruda is funded in New Zealand for treating advanced melanoma, and recently funding was also approved for lung cancer. In Australia, Keytruda has been funded for advanced TNBC since 1st September 2023. BCAC applied for Pharmac funding for both of the breast cancer indications (early and metastatic) in 2022, and we await their decisions. Pharmaceutical company Merck Sharp and Dohme (MSD) has also now applied to Pharmac for use in early and metastatic breast cancer.
Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate that blocks cancer cell proliferation by interfering with DNA repair. The antibody sacituzumab targets the drug to a DNA-enzyme (topoisomerase 1) complex in the cell and the govitecan molecule binds to the DNA and causes it to break, thus halting cell replication. In April 2020, a Phase III trial called ASCENT was stopped early because sacituzumab-govitecan worked so well in patients with metastatic triple negative breast cancer, it was not necessary to continue the trial. On this evidence, sacituzumab govitecan was given accelerated approval by the FDA in the United States in April 2020. It is publicly funded in Australia (March 2022) and England (July 2022), but is not approved by Medsafe or funded by Pharmac in New Zealand. BCAC is in discussion with Gilead Sciences to import Trodelvy and implement a cost share programme while they apply for Medsafe registration. Gilead has stated they are passionate about bringing Trodelvy into New Zealand for the benefit of New Zealanders with breast cancer. We are hopeful they will apply for registration by the end of 2023 and implement a cost share programme even sooner. In addition to the triple negative breast cancer indication, in July 2023 Gilead was granted registration of Trodelvy for use in Australia in hormone receptor-positive/HER2-negative metastatic breast cancer. This was on the basis of the TROPiCS-02 clinical trial that showed an overall survival benefit over chemotherapy for mHR+/HER2- breast cancer, independent of HER2-low status.
Trastuzumab biosimilars (various brand names). Trastuzumab (brand name Herceptin®) was developed in the United States in the 1990s by pharmaceutical research and development company Genentech and was first approved for use as a targeted therapy for HER2-positive breast cancer in the USA in 1998. Genentech was bought by pharmaceutical company Roche in 2006.
Trastuzumab is a ‘biologic’ medicine – it is a monoclonal antibody that has to be grown in a living cell culture system, rather than a drug that can be produced by a purely chemical reaction. The patents on Herceptin expired in Europe in 2014 and in the United States in 2019. This has allowed other companies to develop biosimilar versions of trastuzumab. A biosimilar is basically a copy of a drug that has been made in a slightly different biological system from the original.
Regulators have developed evaluation processes aimed at ensuring that biosimilars are highly similar to the original product, in terms of their efficacy and safety, including clinical trials in some cases. However, biosimilars will not have to go through the extensive clinical trials that the original products did. It is likely that any subtle differences will become evident only as clinicians gain experience in prescribing these medicines and their patients report their experiences with them. This has been the case for generic medicines, which are complete copies of chemical (not biologic) drugs. These should be identical molecules to the original, but sometimes they can produce different effects in some patients.
Currently, Herceptin (supplied by Roche) is the only version of trastuzumab that is publicly funded by Pharmac in New Zealand, but there are several biosimilars now on the global market. This competitive situation has led to price reductions. Four trastuzumab biosimilars have been approved by Medsafe NZ – Herzuma® (supplied by Celltrion), Ogivri® (supplied by Mylan and Biocon Biologics), Trazimera® (supplied by Pfizer), and Kanjinti® (supplied by Amgen). A fifth, Ontruzant® (supplied by Merck) has not yet been approved by Medsafe. All five trastuzumab biosimilars are now publicly funded in Australia.
Pharmac’s website shows an application for funding Herzuma was lodged by Celltrion in May 2019 and in October 2019 the Cancer Treatments Subcommittee noted the potential for cost savings with this product. BCAC is mystified as to why Pharmac did not move quickly to tender for a trastuzumab biosimilar given the substantial cost savings likely. However, in June 2023 Pharmac finally tendered for an infusible biosimilar trastuzumab and is set to begin funding Herzuma for both early stage and advanced HER2 positive breast cancer from 1st November 2023. This product has been used safely and effectively in Australia and in private clinics in New Zealand since 2019. Read BCAC's response to Pharmac's trastuzumab biosimilar consultation here.
Trastuzumab as a re-treatment (various brand names) for advanced HER2-positive breast cancer. Trastuzumab (original brand name Herceptin®) has been funded for use in the treatment of early HER2-positive breast cancer in New Zealand since 2008. It can also be used to treat advanced breast cancer, but Pharmac has limited this to a single use. Once a patient’s cancer progresses on this medicine, it cannot be used again in New Zealand. However, European and all other international guidelines state that it should be available for this purpose and Australia and many other countries do fund re-treatment with trastuzumab under these circumstances. The HER2CLIMB clinical trial has shown that people with advanced HER2-positive breast cancer who had been previously treated with trastuzumab (Herceptin), pertuzumab (Perjeta) and trastuzumab emtansine (Kadcyla) and were then re-treated with trastuzumab along with tucatinib (Tukysa, see below) and capecitabine chemotherapy had longer before their cancer advanced and lived longer.
Researchers involved in Breast Cancer Trials (Australia and NZ) (BCT) have started a new clinical trial, TUGETHER, that will test a combination of Tukysa, pembrolizumab (Keytruda) and trastuzumab re-treatment in advanced HER2-positive breast cancer. BCT wanted to involve NZ patients in this trial and this would provide an exciting opportunity for some NZ women to gain early access to a very promising combination of treatments. Sadly, because Pharmac does not fund the basic backbone of this trial, trastuzumab re-treatment, NZ patients are ineligible for the trial.
When Pharmac announced a tender for a biosimilar trastuzumab to replace Herceptin in June 2023 BCAC was saddened to see that despite the cost savings that would be made they did not propose to extend funding to retreatment. We made a strong case that Pharmac should follow international best practice and offer this treatment option to New Zealanders, but the decision was not changed. Instead, we were told that the evidence we had submitted would be considered at an unspecified future meeting of the same committee that had failed to recommend retreatment in the first place. Read BCAC's views on Pharmac's trastuzumab biosimilar proposal and exclusion of retreatment here.
Sub-cutaneous trastuzumab is an alternative formulation of trastuzumab that can be given by injection rather than by intravenous infusion. This has huge benefits in terms of convenience and efficiency as it can be administered without a lengthy visit to an infusion centre at a hospital. Australia funds this version of this medicine but New Zealand does not. The supplier applied to Pharmac for funding in 2013, but was told in 2015 that it would only be considered if the product could be made “cost-neutral”, i.e. the same as the intravenous formulation. There has been no further progress with this.
Sub-cutaneous trastuzumab + pertuzumab (brand name Phesgo®), like sub-cutaneous trastuzumab, is given as an injection rather than a lengthy infusion. It contains both Herceptin® and Perjeta® premixed in a syringe. Roche applied for funding for Phesgo® in early (both neo-adjuvant and adjuvant settings) and metastatic breast cancer. PTAC has deferred the application for both the early indications as data are awaited from the APHINITY trial (due 2024), and has recommended it for metastatic breast cancer only if it is cost-neutral compared with the dual infusion of Herceptin® and Perjeta®.
Trastuzumab emtansine (brand name Kadcyla®) re-treatment after recurrence. This medicine has been funded in New Zealand since 2019 for women whose HER2-positive breast cancer has advanced. Recent research has shown that it is also useful for treating some women with early HER2-positive breast cancer who are at high risk of recurrence. New Zealand has followed Australia’s example and has funded trastuzumab emtansine for this group of women with early breast cancer. However, if their cancer returns in future, Pharmac will not fund them to receive it again, even though this could be of benefit. For more on this read here.
Vinorelbine oral capsules are an alternative formulation of a cytotoxic chemotherapy drug usually given intravenously for advanced breast cancer. Both forms of vinorelbine are funded in Australia. In New Zealand, the oral form was first applied for in 2007. Over the years, intravenous vinorelbine has beenfunded but the capsules have not, even though their use would have saved time and effort not only for patients, but also for hospital infusion centre staff. Pharmac has finally agreed in December 2022 to fund the capsule form and this has finally been made available as of 1st May 2023, 16 years after the first request.
Breast cancer medicines recommended in European guidelines but not funded in Australia or New Zealand (May 2023)
Alpelisib (brand name PIQRAY®) is an inhibitor of an enzyme called PI3K which is part of a biochemical pathway that normally controls cell proliferation in our bodies. In some cancers, the gene encoding PI3K is mutated (called a PIK3CA mutation) and PI3K is over-expressed, contributing to tumour growth. Alpelisib can inhibit PI3K and help to reduce the growth of cancer cells. Novartis, the manufacturer of alpelisib, supplies it along with a test for the PIK3CA mutation, as a product called PIQRAY.
In May 2019 the USA FDA approved PIQRAY for use with fulvestrant to treat those whose advanced hormone receptor-positive, HER2-negative, PIK3CA-mutant breast cancer had progressed on endocrine therapy. In the SOLAR-1 phase III clinical trial, those receiving this combination had had median progression-free survival of 11.0 months, compared to only 5.7 months for those receiving fulvestrant alone. There is a similar Australian-based clinical trial with alpelisib (called CAPTURE) under way at present (July 2022). PIQRAY was funded in England in July 2022.
Atezolizumab (brand name Tecentriq®) is an immunotherapy medicine for metastatic triple negative breast cancer (TNBC). Tecentriq has been shown (in the Impassion130 clinical trial) to improve survival in patients with metastatic triple negative breast cancer whose tumours have high PD-L1 expression. In March 2020, Tecentriq was provisionally funded in Australia for use with nab-paclitaxel to treat metastatic triple negative breast cancer patients with high levels of PD-L1; final approval will depend on further evidence of benefit. NICE (medicines assessor) in the United Kingdom recommended Tecentriq for a similar use in May 2020. Tecentriq is Medsafe-approved in New Zealand, but not Pharmac-funded. However, Tecentriq supplier Roche has applied to Pharmac for it to be funded and at present offers a Cost Share Programme (contact firstname.lastname@example.org for more information). Pharmac is awaiting results from the Impassion 131 and 132 studies before making a decision.
Margetuximab (brand name Margenza®) is an immunotherapy treatment for those who have advanced HER2-positive breast cancer and have already received two or more other medicines that target HER2. Margetuximab is not Medsafe-registered or funded in New Zealand.
Neratinib (brand name Nerlynx®) is a tyrosine kinase inhibitor. Tyrosine kinases are enzymes that play important roles in normal cell growth and metabolism. In some cancers, tyrosine kinases are abnormally activated and so inhibiting them could be effective in controlling the cancer. In February 2020, the United States FDA approved neratinib in combination with the chemotherapy drug capecitabine for those whose advanced HER2-positive breast cancer had progressed on two previous lines of anti-HER2 therapy (such as Herceptin (trastuzumab), Perjeta (pertuzumab) or Kadcyla (trastuzumab emtansine)). Recent research results have shown that it is also effective in treating early breast cancer that is both HER2-positive and hormone receptor-positive. In New Zealand, Nerlynx was approved by Medsafe in June 2020. It is not funded by Pharmac.
Olaparib (brand name Lynparza®) is a PARP inhibitor which was originally approved and funded in New Zealand and Australia only for ovarian cancer in those carrying a BRCA gene mutation. However, olaparib is also now registered in both countries for germline BCRA-mutated HER2-negative metastatic breast cancer. Olaparib is not funded for this indication in either country, but BCAC is considering applying to Pharmac for funding.
The new breast cancer indication was based on extended follow-up of the OlympiAD clinical trial, which showed survival benefits for those receiving olaparib instead of standard chemotherapy treatments for germline BCRA-mutated HER2-negative metastatic breast cancer. The greatest benefit was seen in those given olaparib as their first-line treatment after being diagnosed with metastatic disease.
Another trial, called OlympiA, has shown that in early stage HER2-negative germline BRCA-mutated breast cancer, olaparib treatment following chemotherapy that was given either before or after surgery improves survival free of invasive or distant disease. The FDA approved this treatment for early breast cancer in March 2022.
Pertuzumab for neoadjuvant treatment (brand name Perjeta®) is another immunotherapy drug that targets the HER2 receptors on breast cancer cells. It is funded as a treatment for advanced HER2-positive breast cancer, but it is also effective when used as a pre-surgery (neo-adjuvant) treatment in patients with early HER2-positive breast cancer and at high risk of recurrence. Pharmaceutical company Roche applied for this use in 2017. It was recommended for decline but following submission of new data it is again under consideration (May 2023).
Talazoparib (brand name Talzenna®) is another PARP inhibitor which can be used to treat advanced triple negative breast cancer. Talzenna is Medsafe-registered but not funded in New Zealand.
Trastuzumab deruxtecan (brand name Enhertu®) is an antibody-drug conjugate composed of trastuzumab, which targets the drug to HER2 receptors on breast cancer cells, and deruxtecan, a cytotoxin which then kills those cells. Clinical trials called DESTINY- Breast03 and DESTINY- Breast04 have recently shown that this medicine improves survival in two groups of patients with advanced breast cancer – those whose HER2-positive cancer has returned after first line treatment with trastuzumab and taxanes, and also those with ‘HER2-low’ advanced cancer. HER2-low is a new category – up until now these cancers have been lumped together in the HER2-negative category. In April 2023 Australia's Pharmaceutical Benefits Advisory Committee recommended funding Enhertu for metastatic HER2-positive breast cancer. Most recently, AstraZeneca, manufacturer of Enhertu, has applied for Medsafe registration for its use in HER2-positive breast cancer and this is being progressed as a priority review, with a decision hoped for by August 2023. AstraZeneca has also applied for funding for this indication, and this was considered at Pharmac’s Cancer Treatments Advisory Committee meeting in April 2023. AstraZeneca plans to implement a cost-share programme for Enhertu once registration is granted, so we await the outcome of the Medsafe application with great interest. Read more about Enhertu here.
Tucatinib (brand name Tukysa®) is a selective HER2 tyrosine kinase inhibitor which was approved by the United States FDA in May 2020 for treatment of advanced HER2-positive breast cancer. Results of the HER2CLIMB clinical trial presented in May 2020 showed that tucatinib combined with capecitabine demonstrated survival benefits in patients who had already progressed after several lines of treatment for their advanced HER2-positive breast cancer. Encouragingly, these benefits were also seen among patients who had brain metastases. Often cancer medicines do not work well for these tumours as there is a ‘blood-brain barrier’ that normally functions to protect the brain, but has the unfortunate side-effect of preventing many medicines from getting into this tissue.
BCAC Committee Member, medical writer and Metavivor Marion Barnett has compiled a detailed summary of medicines for advanced breast cancer that are recommended in international guidelines and funded in Australia vs New Zealand. Read Marion's summary here.
4th September 2023